Idarucizumab

Reversal agents for the management of oral anticoagulant-associated ICH 3:40
Reversal agents for the management of oral anticoagulant-associated ICH
Ashkan Shoamanesh • 5 Jun 2023
SOP for idarucizumab application in stroke patients taking dabigatran 5:40
SOP for idarucizumab application in stroke patients taking dabigatran
Senta Frol • 30 Mar 2023
Reversal agents prior to IVT in patients taking DOACs 5:11
Reversal agents prior to IVT in patients taking DOACs
Senta Frol • 30 Mar 2023
How is oral anticoagulant-associated intracerebral hemorrhage currently managed? 4:51
How is oral anticoagulant-associated intracerebral hemorrhage currently managed?
Hanne Christensen • 21 Oct 2022
The value of specific reversal agents in stroke management 6:00
The value of specific reversal agents in stroke management
Senta Frol • 17 May 2022
Idarucizumab reversal of dabigatran in acute ischemic stroke and intracranial hemorrhage 5:31
Idarucizumab reversal of dabigatran in acute ischemic stroke and intracranial hemorrhage
Senta Frol • 17 May 2022
The content of VJNeurology is intended for healthcare professionals